ArticleTherapeutic advances in neurological disorders2013
Recent developments in the treatment of Duchenne muscular dystrophy and spinal muscular atrophy.
Article in Therapeutic advances in neurological disorders, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- DG9-Conjugated Morpholino-Based Exon 51-Skipping Therapy for Duchenne Muscular Dystrophy.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Ambulatory Duchenne muscular dystrophy children: cross-sectional correlation between function, quantitative muscle ultrasound and MRI.Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology · 2022Article
- Targeting IRES-dependent translation as a novel approach for treating Duchenne muscular dystrophy.RNA biology · 2021Review
- Receptor-Mediated Muscle Homeostasis as a Target for Sarcopenia Therapeutics.Endocrinology and metabolism (Seoul, Korea) · 2021Review
- Borax-loaded injectable alginate hydrogels promote muscle regeneration in vivo after an injury.Materials science & engineering. C, Materials for biological applications · 2021Article
- Renal involvement in the pathogenesis of mineral and bone disorder in dystrophin-deficient mdx mouse.The journal of physiological sciences : JPS · 2019Article
- Nutritional Challenges in Duchenne Muscular Dystrophy.Nutrients · 2017Review
- Foetal surgery and using in utero therapies to reduce the degree of disability after birth. Could it be morally defensible or even morally required?Medicine, health care, and philosophy · 2017Article
- Stability and sensitivity of water TNMR in biomedicine · 2016Article
- Health-Related Quality of Life in Children with Duchenne Muscular Dystrophy: A Review.Journal of neuromuscular diseases · 2015Article
- Erythropoietin reduces the expression of myostatin in mdx dystrophic mice.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2014Article
- MicroRNA-486-dependent modulation of DOCK3/PTEN/AKT signaling pathways improves muscular dystrophy-associated symptoms.The Journal of clinical investigation · 2014Article
- Gene-environment interactions in severe intraventricular hemorrhage of preterm neonates.Pediatric research · 2014Review
- The new frontier of genetically targeted therapies for muscle disease.Continuum (Minneapolis, Minn.) · 2013Article
- Fast detection of deletion breakpoints using quantitative PCR.Genetics and molecular biologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Pediatric neuromuscular disorders comprise a large variety of disorders that can be classified based on their neuroanatomical localization, patterns of weakness, and laboratory test results. Over the last decade, the field of translational research has been active with many ongoing clinical trials. This is particularly so in two common pediatric neuromuscular disorders: Duchenne muscular dystrophy and spinal muscular atrophy. Although no definitive therapy has yet been found, numerous active areas of research raise the potential for novel therapies in these two disorders, offering hope for improved quality of life and life expectancy for affected individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.